Business Context and Reporting Period
This summary covers the Form 10-Q filed by Rexahn Pharmaceuticals, Inc. (Note: Metadata listed "Opus Genetics," but the filing text identifies the registrant as Rexahn Pharmaceuticals) for the quarterly period ended June 30, 2009. Rexahn is a development-stage biopharmaceutical company focused on discovering and developing treatments for cancer, central nervous system disorders, and sexual dysfunction. The company has not yet generated commercial product sales and relies on equity financing, debt, and research contributions to fund operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Total Revenues | $37,500 | $37,500 |
| Total Expenses | $3,331,043 | $2,233,526 |
| Net Loss | $(3,267,616) | $(2,050,274) |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.04) |
| Cash and Cash Equivalents (End of Period) | $4,193,615 | $1,206,322 |
| Accumulated Deficit (Inception to Date) | $(33,174,095) | $(29,906,479) |
| Net Cash Used in Operating Activities | $(2,402,223) | $(2,124,682) |
| Net Cash Provided by Financing Activities | $2,775,000 | $919,201 |
Liquidity and Debt: The company reported no long-term debt on the balance sheet as of June 30, 2009. Total current liabilities were $1,781,190, primarily consisting of deferred revenue ($1,012,500) and accounts payable/accrued expenses ($768,690). The company holds $100,000 in restricted cash equivalents related to a letter of credit for a new office lease.
Material Changes vs. Prior Period
- Revenue: Remained flat at $37,500 for the six-month period, derived entirely from the amortization of a deferred revenue agreement with Rexgene Biotech Co., Ltd.
- Expenses: Total expenses increased by approximately 49% year-over-year.
- Research and Development (R&D): Increased 87.3% to $1,594,157, driven by the expansion of multiple clinical studies for drug candidates Archexin, Serdaxin, and Zoraxel.
- General and Administrative (G&A): Increased 25.1% to $1,561,737, primarily due to higher audit fees (Sarbanes-Oxley compliance) and increased stock option compensation.
- Cash Position: Cash and cash equivalents increased significantly from $369,130 at year-end 2008 to $4,193,615 at June 30, 2009. This was driven by the sale of marketable securities ($4.76M proceeds) and a private equity placement ($2.78M net proceeds).
- Investments: The company sold all marketable securities held at the end of 2008, realizing a gain of $11,025.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- Management believes existing cash resources are sufficient to fund operations through June 30, 2010.
- Projected minimum spending for the next 12 months includes approximately $1.4 million for Phase II clinical trials, $2.6 million for general corporate expenses, and $76,524 for rent.
- Full implementation of the operating plan, including pre-clinical studies and new trials, could require up to $4.2 million, necessitating additional financing.
- If additional capital is not secured, the company plans to reduce R&D activities, starting with pre-clinical compounds.
Risks and Contingencies:
- Legal Proceedings: Amarex, LLC filed a lawsuit alleging breach of contract seeking $93,156 plus interest. Rexahn filed a counterclaim for $354,824. The case is in non-binding mediation.
- Regulatory Review: FINRA is reviewing trading in the company's stock surrounding a May 2009 announcement regarding the drug candidate Zoraxel.
- Listing Status: The company regained compliance with NYSE Amex listing standards in July 2009, removing the immediate threat of delisting.
- Going Concern: As a development-stage company with an accumulated deficit of over $33 million, the company requires continued capital raises to sustain operations and complete clinical trials.
Investor Verification Checklist
- Cash Runway: Verify if the $4.2 million funding gap for full operations has been addressed since the filing date (August 2009).
- Legal Resolution: Monitor the status of the Amarex, LLC litigation and counterclaim to assess potential financial impact.
- Clinical Trial Progress: Confirm the status and cost estimates for Phase II trials of Archexin (pancreatic/renal cancer), Serdaxin (depression), and Zoraxel (sexual dysfunction).
- Equity Dilution: Review subsequent equity issuances, noting the significant warrant issuances (Series I, II, and III) attached to the May 2009 financing.
- Revenue Recognition: Understand that current revenue is non-recurring (amortization of a 2003 agreement) and does not reflect product sales.